• Kincell Bio and Cellipont Bioservices completed a merger to form Kincellis Advanced Therapies, a U.S.-based CDMO focused on cell therapies.
• Equity financing for the transaction was led by NewSpring Capital, with support from Kineticos Life Sciences, HealthQuest Capital, Great Point Partners.
• J.P. Morgan provided a debt facility tied to the deal; financial terms were not disclosed.
• Kincellis operates about 140,000 square feet across three U.S. sites, with 16 qualified GMP suites supporting clinical to commercial supply.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kineticos Life Sciences Management LLC published the original content used to generate this news brief on September 17, 2026, and is solely responsible for the information contained therein.